GALT

Insider Trades

Name	Value	Action	Price	Current Price
Jamil KhurramChief Medical Officer $1.8k568 shares SellMay 26, 2026 $3.10 --
Eldred KaryDirector $810300 shares BuyFeb 6, 2026 $2.70 --
Lewis JoelDirector, Officer: President And CEO $135k37.7k shares SellJan 6, 2026 $3.58 --
Jamil KhurramChief Medical Officer $78k21.4k shares SellJan 6, 2026 $3.65 --
Callicutt Jack WChief Financial Officer $75k20.4k shares SellJan 6, 2026 $3.67 --
Lewis JoelDirector, Officer: President And CEO $108k27.7k shares SellJan 5, 2026 $3.91 --

News

globenewswire.comGalectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosisglobenewswire.comMay 27

globenewswire.comGalectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Updateglobenewswire.comMay 15

globenewswire.comGalectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatologyglobenewswire.comMay 11

globenewswire.comGalectin Therapeutics, Inc. Investigated by the Portnoy Law Firmglobenewswire.comApr 27

zacks.comGalectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?zacks.comApr 3

Trade GALT

About Galectin Therapeutics Inc.

Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.

CEO: Joel Lewis
IPO Date: Sep 4, 2002

Market Data

Open: $2.42
High: $2.54
Low: $2.38
Volume: 294.8K
52W High: $7.13
52W Low: $1.30

Valuation

Market Cap: $159M
Enterprise Value: $280M

Financials

Free Cash Flow: $-24M
Revenue: $0
Net Income: $-31M
Cash: $18M
Debt: $134M

Events

EarningsAug 13

EPS est. -0.09